WO2006076927A2 - General solvent synthesis, production and utility - Google Patents

General solvent synthesis, production and utility Download PDF

Info

Publication number
WO2006076927A2
WO2006076927A2 PCT/EG2006/000004 EG2006000004W WO2006076927A2 WO 2006076927 A2 WO2006076927 A2 WO 2006076927A2 EG 2006000004 W EG2006000004 W EG 2006000004W WO 2006076927 A2 WO2006076927 A2 WO 2006076927A2
Authority
WO
WIPO (PCT)
Prior art keywords
added
combination
entries
effective
medical conditions
Prior art date
Application number
PCT/EG2006/000004
Other languages
French (fr)
Inventor
Magd Ahmed Kotb Abdalla
Original Assignee
Magd Ahmed Kotb Abdalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2007555455A priority Critical patent/JP2008528793A/en
Application filed by Magd Ahmed Kotb Abdalla filed Critical Magd Ahmed Kotb Abdalla
Priority to MX2007008979A priority patent/MX2007008979A/en
Priority to BRPI0614031-9A priority patent/BRPI0614031A2/en
Priority to AP2007004107A priority patent/AP2007004107A0/en
Priority to CA002594768A priority patent/CA2594768A1/en
Priority to EP06704104A priority patent/EP1851300A4/en
Priority to AU2006207750A priority patent/AU2006207750A1/en
Priority to EA200701435A priority patent/EA200701435A1/en
Priority to CNA2006800030369A priority patent/CN101107350A/en
Publication of WO2006076927A2 publication Critical patent/WO2006076927A2/en
Priority to IL184597A priority patent/IL184597A0/en
Priority to TNP2007000271A priority patent/TNSN07271A1/en
Priority to NO20074191A priority patent/NO20074191L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/66—Non-ionic compounds
    • C11D1/835—Mixtures of non-ionic with cationic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/86—Mixtures of anionic, cationic, and non-ionic compounds
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/02—Inorganic compounds ; Elemental compounds
    • C11D3/04—Water-soluble compounds
    • C11D3/046—Salts
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/02—Inorganic compounds
    • C11D7/04—Water-soluble compounds
    • C11D7/10—Salts
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C11D7/268—Carbohydrates or derivatives thereof

Definitions

  • Detergents are formed of surface compounds which are not environmentally safe. They are either natural or synthetic. Oil soluble detergents are used in gasoline and lubricating oils to hold particulate impurities in suspension. Among the water soluble detergents, alcohols and common soaps are effective. Still more so are the synthetic types (syndets) such as sulphonated dodecylbenzene and similar alkylates. The linear alkyl sulphonates (LAS) are more biodegradable than are the branched-chain type; they are made from petrochemicals by various cracking and polymerization techniques. Three general types of detergents are in use; anionic, cationic, and non-ionic.
  • shock wave lithotripsy is used, or surgically, or medicines to change ph of urine to prevent further stone formation.
  • Calcium is essential for human and animal cells where it is essential as an integral part of bone mineral, an integral part of the cell wall and its biological function, the essential link between excitation and contraction in all forms of muscle, the essential link between excitation and secretion in both endocrine and exocrine glands and an activator, regulator or inhibitor of key enzymes.
  • Glucose is essential for absorption of other solutes.
  • the preparation of any of the mixtures described in this patent includes glucose or a carbohydrate in different proportions.
  • Solubility rules include; -All salts of the alkali metals are soluble, - All salts of the ammonium ion NH 4 + are soluble, - All salts of nitrate ion (NO 3 " ) are soluble, - All salts of chlorate ion (ClO 3 " ) are soluble, - All salts of perchlorate ion (ClO 4 " ) are soluble, - All salts of acetate ion (C 2 H 3 O 2 " ) are soluble, - All chlorides, bromides, and iodides (except Ag + , Pb + , and Hg 2 2+ ) are soluble, - All sulphates (SO 4 2" ) (except those of Ca 2+ , Sr 2+ , Ba 2+ and Pb + ) are soluble, - All metal oxides .are insoluble, except those of alkali metals, Ca 2+ , Sr 2+ , Ba

Description

General solvent synthesis, production and utility
Technical Field:
1. Medicine
2. Chemistry
Background Art:
Detergents are formed of surface compounds which are not environmentally safe. They are either natural or synthetic. Oil soluble detergents are used in gasoline and lubricating oils to hold particulate impurities in suspension. Among the water soluble detergents, alcohols and common soaps are effective. Still more so are the synthetic types (syndets) such as sulphonated dodecylbenzene and similar alkylates. The linear alkyl sulphonates (LAS) are more biodegradable than are the branched-chain type; they are made from petrochemicals by various cracking and polymerization techniques. Three general types of detergents are in use; anionic, cationic, and non-ionic.
To overcome tissue metastatic calcification or stones developing in various duct systems of human body as renal stones or gall bladder stones shock wave lithotripsy is used, or surgically, or medicines to change ph of urine to prevent further stone formation.
Calcium is essential for human and animal cells where it is essential as an integral part of bone mineral, an integral part of the cell wall and its biological function, the essential link between excitation and contraction in all forms of muscle, the essential link between excitation and secretion in both endocrine and exocrine glands and an activator, regulator or inhibitor of key enzymes.
Glucose is essential for absorption of other solutes. Depending on this solute drag the preparation of any of the mixtures described in this patent includes glucose or a carbohydrate in different proportions.
Disclosure of Invention:
Solubility rules include; -All salts of the alkali metals are soluble, - All salts of the ammonium ion NH4 + are soluble, - All salts of nitrate ion (NO3 ") are soluble, - All salts of chlorate ion (ClO3 ") are soluble, - All salts of perchlorate ion (ClO4 ") are soluble, - All salts of acetate ion (C2H3O2 ") are soluble, - All chlorides, bromides, and iodides (except Ag+, Pb+, and Hg2 2+) are soluble, - All sulphates (SO4 2") (except those of Ca2+, Sr2+, Ba2+ and Pb+) are soluble, - All metal oxides .are insoluble, except those of alkali metals, Ca2+, Sr2+, Ba2+ , - All carbonates (CO3 2") are insoluble, except those of alkali metals, and ammonium salts, - All phosphates (PO4 3") are insoluble, except those of alkali metals, and ammonium (NH4 +) salts, - All sulfides (S2 " ) are insoluble, except those of alkali metals, and ammonium salts.
The Novel Idea:
Using a mixture of different or any combinations of aqueous or anhydrous or molar volumes of these soluble salts is capable of :
1. Stain removal.
2. Functioning as a general solvent for any purpose.
3. Functioning as a general solvent for human or animal tissue calcification.
4. Functioning as a general solvent for human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc.,
5. Delivering soluble calcium ions in medical conditions of convulsions and epilepsy of any aetiology.
6. Delivering soluble sodium and potassium ions in medical conditions of convulsions and epilepsy of any aetiology.
7. Delivering soluble calcium ions in medical conditions of osteoporosis of any aetiology.
8. Delivering soluble calcium ions in medical conditions of bone resorption of any aetiology.
9. Delivering soluble calcium ions in medical conditions of bone disease of any aetiology.
10. Delivering soluble calcium ions in medical conditions of cardiac arrhythmias of any aetiology.
11.Delivering soluble sodium and potassium ions in medical conditions of cardiac arrhythmias of any aetiology.
12. Delivering soluble ions in medical conditions of loss of transparency of eye lens, cornea, aqueous or vitreous body or loss of transparency of any component of eye of any aetiology. 13. Delivering soluble ions in medical conditions associated with development of atheromatous plaques in any site of human or animal body of any aetiology.
14. Delivering soluble ions in medical conditions associated with development of nervous system plaques in any site of human or animal body of any aetiology.
15. Delivering soluble ions in medical conditions associated with impulse conduction defects in any site of human or animal body of any aetiology.
16. Providing oxidation of aldoses to uronic acid and subsequent glucoronization of all substances in need for hepatic glucouronization.
Detailed Description of the Requested Patent:
Manufacturing, producing, preparing and processing a mixture of different combinations of anhydrous or aqueous or molar volumes of the following soluble salts : a- All salts of the alkali metals, b- All salts of the ammonium ion NH4 +, c- All salts of nitrate ion (NO3 "), d- All salts of chlorate ion (ClO3 '), e- All salts of perchlorate ion (ClO4 "), f- All salts of acetate ion (C2H3O2 "), g- All chlorides, bromides, and iodides (except Ag+, Pb+, and Hg2 2+), h- All sulphates (SO4 2") (except those of Ca2+, Sr2+, Ba2+ and Pb+), i- Oxides of alkali metals, Ca2+, Sr2+, Ba2+ , and Manganese j- Carbonates (CO3 2") of alkali metals, and ammonium salts, k- Phosphates (PO4 3") of alkali metals, and ammonium (NH4 +) salts,
1- Sulfides (S2 ") of alkali metals, and ammonium salts. m- Any single or all and any combination of carbohydrates. n- Any and all types of natural Honey.
Where:
i. All of "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general stain remover, ii. All of "a", "b", "c", "d"5 "e", "f", "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d"5 "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for any purpose. iii. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for prevention of human or animal tissue calcification. iv. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for prevention of human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc., v. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for human or animal tissue calcification. vi. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc., vii. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of convulsions and epilepsy of any aetiology. viii. All of "a", "b"3 "c", "d", "e", "F , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h"3 "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of osteoporosis of any aetiology. ix. All of "a", "b", "c", "d", "e", "F , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to V or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of bone resoiption of any aetiology. x. All of "a", "b", "c", "d", "e", "f" , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of bone disease of any aetiology. xi. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k"5 and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of cardiac arrhythmias of any aetiology. xii. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of loss of transparency of eye lens, cornea, aqueous or vitreous body or loss of transparency of any component of eye of any aetiology. xiii. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with development of atheromatous plaques in any site of human or animal body of any aetiology. xiv. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d"3 "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with development of nervous system plaques in any site of human or animal body of any aetiology. xv. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added . to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with impulse conduction defects in any site of human or animal body of any aetiology. xvi. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d"5 "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with need for glucoronization of any and all substances in need for hepatic glucouronization. xvii. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with need for glucoronization of any and all drug overdose or intoxication in need for hepatic glucouronization.

Claims

ClaimsI claim:Manufacturing, producing, preparing and processing a mixture of different combinations of anhydrous or aqueous or in any quantities or molar volumes of the following soluble salts : a- All salts of the alkali metals, b- All salts of the ammonium ion NH4+, c- All salts of nitrate ion (N(V), d- All salts of chlorate ion (ClO3"), e- All salts of perchlorate ion (ClO4"), f- All salts of acetate ion (C2H3O2"), g- All chlorides, bromides, and iodides (except Ag+, Pb+, and Hg22+), h- All sulphates (SO42") (except those of Ca2+, Sr2+, Ba2+ and Pb+), i- Oxides of alkali metals, Ca2+, Sr2+, Ba2+ , and manganese j- Carbonates (CO32") of alkali metals, and ammonium salts, k- Phosphates (PO43") of alkali metals, and ammonium (NH4+) salts, 1- Sulfides (S2") of alkali metals, and ammonium salts, m- Any single or all and any combination of carbohydrates, n- Any and all types of natural Honey.Where:
1. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general stain remover.
2. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for any purpose.
3. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for prevention of human or animal tissue calcification.
4. All of "a", "b", "c'\ "d", "e", "f , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for prevention of human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc.,
5. All of "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for human or animal tissue calcification.
6. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc.,
7. All of "a", "b", "c", "d", "e", "F5 "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of convulsions and epilepsy of any aetiology.
8. All of "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of osteoporosis of any aetiology.
9. All of "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of bone resorption of any aetiology.
10.A11 of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d"5 "e", "F , "g", "h"5 "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of bone disease of any aetiology.
11. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c"3 "d", "e", "F , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of cardiac arrhythmias of any aetiology.
12. All of "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of loss of transparency of eye lens, cornea, aqueous or vitreous body or loss of transparency of any component of eye of any aetiology.
13. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with development of atheromatous plaques in any site of human or animal body of any aetiology.
14. All of "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with development of nervous system plaques in any site of human or animal body of any aetiology.
15. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with impulse conduction defects in any site of human or animal body of any aetiology.
16. All of "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with need for glucoronization of any and all substances in need for hepatic glucouronization.
17. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with need for glucoronization of any and all drug overdose or intoxication in need for hepatic glucouronization.
PCT/EG2006/000004 2005-01-24 2006-01-22 General solvent synthesis, production and utility WO2006076927A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP06704104A EP1851300A4 (en) 2005-01-24 2006-01-22 General solvent synthesis, production and utility
MX2007008979A MX2007008979A (en) 2005-01-24 2006-01-22 General solvent synthesis, production and utility.
BRPI0614031-9A BRPI0614031A2 (en) 2005-01-24 2006-01-22 manufacture, production, preparation and processing of a mixture of different combinations of anhydrous or aqueous volumes or in any molar amounts or volumes of the following soluble salts
AP2007004107A AP2007004107A0 (en) 2005-01-24 2006-01-22 General solvent synthesis, production an dutility
CA002594768A CA2594768A1 (en) 2005-01-24 2006-01-22 General solvent synthesis, production and utility
JP2007555455A JP2008528793A (en) 2005-01-24 2006-01-22 Synthesis, production and use of common solvents
AU2006207750A AU2006207750A1 (en) 2005-01-24 2006-01-22 General solvent synthesis, production and utility
EA200701435A EA200701435A1 (en) 2005-01-24 2006-01-22 GENERAL SYNTHESIS OF SOLVENT, PRODUCTION AND APPLICATION
CNA2006800030369A CN101107350A (en) 2005-01-24 2006-01-22 Synthesis, producing and use for general solvent
IL184597A IL184597A0 (en) 2005-01-24 2007-07-12 Manufacture of a solvent mixture
TNP2007000271A TNSN07271A1 (en) 2005-01-24 2007-07-13 General solvent synthesis,production and utility
NO20074191A NO20074191L (en) 2005-01-24 2007-08-15 General solvent synthesis, preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005010036 2005-01-24
EG2005010036 2005-01-24

Publications (1)

Publication Number Publication Date
WO2006076927A2 true WO2006076927A2 (en) 2006-07-27

Family

ID=36692595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2006/000004 WO2006076927A2 (en) 2005-01-24 2006-01-22 General solvent synthesis, production and utility

Country Status (16)

Country Link
EP (1) EP1851300A4 (en)
JP (1) JP2008528793A (en)
KR (1) KR20070101355A (en)
CN (1) CN101107350A (en)
AP (1) AP2007004107A0 (en)
AU (1) AU2006207750A1 (en)
BR (1) BRPI0614031A2 (en)
CA (1) CA2594768A1 (en)
EA (1) EA200701435A1 (en)
IL (1) IL184597A0 (en)
MA (1) MA29249B1 (en)
MX (1) MX2007008979A (en)
NO (1) NO20074191L (en)
TN (1) TNSN07271A1 (en)
WO (1) WO2006076927A2 (en)
ZA (1) ZA200706091B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382329A1 (en) * 1999-09-02 2001-03-08 Ricky Ah-Man Woo Method of deodorizing and/or cleaning carpet using a composition comprising odor control agent
JP4542279B2 (en) * 2001-03-30 2010-09-08 株式会社ファンケル Cleaning composition
JP2002322491A (en) * 2001-04-23 2002-11-08 Fancl Corp Cleansing composition
JP4625595B2 (en) * 2001-06-06 2011-02-02 塩水港精糖株式会社 Skin cleanser
US6787511B2 (en) * 2002-08-14 2004-09-07 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Biphasic composition induced by polydextrose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1851300A2 *

Also Published As

Publication number Publication date
KR20070101355A (en) 2007-10-16
TNSN07271A1 (en) 2008-12-31
EP1851300A4 (en) 2010-04-14
CA2594768A1 (en) 2006-07-27
MX2007008979A (en) 2007-09-21
NO20074191L (en) 2007-08-15
IL184597A0 (en) 2007-10-31
AU2006207750A1 (en) 2006-07-27
CN101107350A (en) 2008-01-16
JP2008528793A (en) 2008-07-31
EP1851300A2 (en) 2007-11-07
BRPI0614031A2 (en) 2011-03-01
EA200701435A1 (en) 2008-10-30
MA29249B1 (en) 2008-02-01
AP2007004107A0 (en) 2007-08-31
ZA200706091B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
US4190462A (en) Dissolving barium sulfate scale with aqueous solutions of salts of carboxymethyl monocyclic macrocyclic polyamines
Li et al. Effects of magnesium on calcium oxalate crystallization
RU2344083C2 (en) Ferric sulphate based phosphate absorbent
AU7801487A (en) Calcium hypochlorite compositions
FR2407253A1 (en) SYNERGIC COMPOSITIONS TO FIGHT AGAINST CORROSION AND INCRUSTATIONS
WO2006076927A2 (en) General solvent synthesis, production and utility
ES8507423A1 (en) Biological sludge hygienisation process.
BR0114251A (en) Granulated sodium carbonate obtained by fluid bed spray granulation and a process for its production
CN1080319A (en) Chlorine-containing disinfecting detergent
SU709662A1 (en) Invert emulsion drilling mud
US1722137A (en) Method of treating water and materials used in connection therewith
JPS5678680A (en) Treatment for water containing fluoride ion
KR0167537B1 (en) Dispersion composition containing water soluble polymer
US3514269A (en) Process for manufacture of dimagnesium aluminosilicate for medical uses
SU620257A1 (en) Land-improving agent for acid sod-podsolic soils
RU2090521C1 (en) Composition for softening of water (variants)
RU2100293C1 (en) Composition for water softening
JPH0124731B2 (en)
JPS6139876B2 (en)
JP2670081B2 (en) Urolithiasis inhibitor
US20060029680A1 (en) Methods of preparing highly concentrated aqueous bromine solutions
SU991032A1 (en) Composition for removing gypsum deposits
SU789413A1 (en) Method of waste water purification from fluorine in fluoride salt production
DE420910C (en) Process for the preparation of double compounds from aliphatic amino acids and inorganic alkali salts
JPH0730473B2 (en) Strong acid solution for cleaning and purification

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 184597

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2594768

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008979

Country of ref document: MX

Ref document number: 12007501584

Country of ref document: PH

Ref document number: 200680003036.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007555455

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006207750

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2007/004107

Country of ref document: AP

Ref document number: 560709

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2006207750

Country of ref document: AU

Date of ref document: 20060122

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6559/DELNP/2007

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2006207750

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006704104

Country of ref document: EP

Ref document number: 1020077019496

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200701435

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2006704104

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0614031

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20070723